Pathophysiology and pharmacologic treatment of venous thromboembolism.

PubWeight™: 0.77‹?›

🔗 View Article (PMID 24102472)

Published in Curr Drug Targets on February 01, 2014

Authors

Jonathan Bain, Douglas R Oyler, Susan S Smyth, Tracy E Macaulay1

Author Affiliations

1: Division of Cardiovascular Medicine, The Gill Heart Institute, UK HealthCare, 900 South Limestone, Lexington, Kentucky 40536, USA. temaca2@email.uky.edu.

Associated clinical trials:

XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis (XENITH) | NCT02506985

Articles citing this

Novel mediators and biomarkers of thrombosis. J Thromb Thrombolysis (2014) 0.77

Articles by these authors

Rap1b is required for normal platelet function and hemostasis in mice. J Clin Invest (2005) 2.46

Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation. Blood (2011) 2.27

Structural basis of substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol (2011) 1.81

Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci U S A (2010) 1.80

Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J Biol Chem (2009) 1.78

Cardiac response to pressure overload in 129S1/SvImJ and C57BL/6J mice: temporal- and background-dependent development of concentric left ventricular hypertrophy. Am J Physiol Heart Circ Physiol (2006) 1.52

Periostin mediates vascular smooth muscle cell migration through the integrins alphavbeta3 and alphavbeta5 and focal adhesion kinase (FAK) pathway. Atherosclerosis (2009) 1.33

Therapeutic potential of autotaxin/lysophospholipase d inhibitors. Curr Drug Targets (2008) 1.27

Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling. Arterioscler Thromb Vasc Biol (2009) 1.23

Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. Mol Endocrinol (2012) 1.21

Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. Circ Res (2008) 1.20

Characterization of a model to independently study regression of ventricular hypertrophy. J Surg Res (2007) 1.19

Src family kinases mediate neutrophil adhesion to adherent platelets. Blood (2006) 1.16

Autotaxin production of lysophosphatidic acid mediates allergic asthmatic inflammation. Am J Respir Crit Care Med (2013) 1.15

Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells. J Biol Chem (2011) 1.11

Integrin αIIbβ3: from discovery to efficacious therapeutic target. Circ Res (2013) 1.11

Plasma levels of sphingosine 1-phosphate are strongly correlated with haematocrit, but variably restored by red blood cell transfusions. Clin Sci (Lond) (2011) 1.10

Mechanism of rapid elimination of lysophosphatidic acid and related lipids from the circulation of mice. J Lipid Res (2013) 1.09

Mice with targeted inactivation of ppap2b in endothelial and hematopoietic cells display enhanced vascular inflammation and permeability. Arterioscler Thromb Vasc Biol (2014) 1.08

A phosphatidic acid binding/nuclear localization motif determines lipin1 function in lipid metabolism and adipogenesis. Mol Biol Cell (2010) 1.07

Src-family kinases mediate an outside-in signal necessary for beta2 integrins to achieve full activation and sustain firm adhesion of polymorphonuclear leucocytes tethered on E-selectin. Biochem J (2006) 1.05

Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway. Nat Commun (2013) 1.05

Lipid phosphate phosphatase 3 negatively regulates smooth muscle cell phenotypic modulation to limit intimal hyperplasia. Arterioscler Thromb Vasc Biol (2012) 1.04

Platelets as immune mediators: their role in host defense responses and sepsis. Thromb Res (2010) 1.04

CX3CR1 deficiency confers protection from intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol (2006) 1.04

Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid. J Lipid Res (2013) 1.03

Thrombosis and antithrombotic therapy in women. Arterioscler Thromb Vasc Biol (2009) 1.03

Individual heterogeneity in platelet response to lysophosphatidic acid: evidence for a novel inhibitory pathway. Arterioscler Thromb Vasc Biol (2008) 1.02

Distinct roles for Rap1b protein in platelet secretion and integrin αIIbβ3 outside-in signaling. J Biol Chem (2011) 1.01

Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice. Am J Physiol Heart Circ Physiol (2009) 0.99

Evidence of mobilization of pluripotent stem cells into peripheral blood of patients with myocardial ischemia. Exp Hematol (2010) 0.92

Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways. Biochem J (2011) 0.91

Enhanced proliferation and migration of vascular smooth muscle cells in response to vascular injury under hyperglycemic conditions is controlled by beta3 integrin signaling. Int J Biochem Cell Biol (2010) 0.91

Functional characterization of the atypical integral membrane lipid phosphatase PDP1/PPAPDC2 identifies a pathway for interconversion of isoprenols and isoprenoid phosphates in mammalian cells. J Biol Chem (2010) 0.90

Measurement of autotaxin/lysophospholipase D activity. Methods Enzymol (2007) 0.90

Platelet secretion and hemostasis require syntaxin-binding protein STXBP5. J Clin Invest (2014) 0.89

Lysophosphatidic acid signaling protects pulmonary vasculature from hypoxia-induced remodeling. Arterioscler Thromb Vasc Biol (2011) 0.87

Bioactive lipids and cationic antimicrobial peptides as new potential regulators for trafficking of bone marrow-derived stem cells in patients with acute myocardial infarction. Stem Cells Dev (2013) 0.87

Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. Coron Artery Dis (2009) 0.86

CD40 is essential in the upregulation of TRAF proteins and NF-kappaB-dependent proinflammatory gene expression after arterial injury. PLoS One (2011) 0.85

Blood relatives: dynamic regulation of bioactive lysophosphatidic acid and sphingosine-1-phosphate metabolism in the circulation. Trends Cardiovasc Med (2009) 0.84

Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils. Arterioscler Thromb Vasc Biol (2007) 0.84

Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thrombolysis (2013) 0.84

Parent-of-origin effects on cardiac response to pressure overload in mice. Am J Physiol Heart Circ Physiol (2009) 0.84

Coronary artery remodeling in a model of left ventricular pressure overload is influenced by platelets and inflammatory cells. PLoS One (2012) 0.83

Integrin-mediated cell surface recruitment of autotaxin promotes persistent directional cell migration. FASEB J (2013) 0.83

Synergistic effect of anemia and red blood cells transfusion on inflammation and lung injury. Adv Hematol (2012) 0.83

Lysophosphatidic acid and cardiovascular disease: seeing is believing. J Lipid Res (2013) 0.82

Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. J Am Coll Cardiol (2012) 0.81

Lysophospholipids in coronary artery and chronic ischemic heart disease. Curr Opin Lipidol (2015) 0.81

Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Thromb Haemost (2014) 0.80

Spontaneous coronary thrombosis following thrombolytic therapy for acute cardiovascular accident and stroke: a case study. J Thromb Thrombolysis (2012) 0.79

Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy. J Thromb Thrombolysis (2011) 0.79

Inflammation and thrombosis in cardiovascular disease. Curr Opin Hematol (2013) 0.79

Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B. Cardiol Rev (2015) 0.79

Enhanced platelet reactivity and thrombosis in Apoe-/- mice exposed to cigarette smoke is attenuated by P2Y12 antagonism. Thromb Res (2010) 0.78

Cardiovascular devices and platelet interactions: understanding the role of injury, flow, and cellular responses. Circ Cardiovasc Interv (2012) 0.78

Antiplatelet therapy in prevention of cardio- and venous thromboembolic events. J Thromb Thrombolysis (2014) 0.78

The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism. PLoS One (2012) 0.78

Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development. Arterioscler Thromb Vasc Biol (2010) 0.78

Rectal propranolol controls paroxysmal sympathetic hyperactivity: a case report. Pharmacotherapy (2015) 0.78

The effect of rosuvastatin on platelet-leukocyte interactions in the setting of acute coronary syndrome. J Am Coll Cardiol (2015) 0.77

Preventing platelet thrombosis with a PAR1 pepducin. Circulation (2012) 0.77

The effect of rosuvastatin on thromboinflammation in the setting of acute coronary syndrome. J Thromb Thrombolysis (2015) 0.77

Novel mediators and biomarkers of thrombosis. J Thromb Thrombolysis (2014) 0.77

In-stent restenosis: more fuel for the fire. Am Heart J (2002) 0.76

Tissue necrosis factor α and targeting its receptor in ischaemic heart disease. Heart (2013) 0.76

Comprehensive Geriatric Assessment for Trauma: Operationalizing the Trauma Quality Improvement Program Directive. J Trauma Nurs (2016) 0.76

Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients. Am Heart J (2010) 0.75

Targeting platelet thrombin receptor signaling to prevent thrombosis. Pharmaceuticals (Basel) (2013) 0.75

Invasive coronary vasoreactivity testing to diagnose microvascular dysfunction in women. JACC Cardiovasc Interv (2012) 0.75

Connexin 37 counteracts clotting. Circulation (2011) 0.75

Anti-Thrombotic Effects of Statins in Acute Coronary Syndromes: At the Intersection of Thrombosis, Inflammation, and Platelet-Leukocyte Interactions. Curr Cardiol Rev (2016) 0.75

Fibrinolytic therapy versus primary percutaneous coronary interventions for ST-segment elevation myocardial infarction in Kentucky: time to establish systems of care? South Med J (2013) 0.75

The Impact of Interventions to Improve Sleep on Delirium in the ICU: A Systematic Review and Research Framework. Crit Care Med (2016) 0.75

Platelet function analysis: at the edge of meaning. Thromb Haemost (2009) 0.75

The case against routine aspirin use for primary prevention in low-risk adults. Am Fam Physician (2011) 0.75

Anti-platelet therapy. Curr Drug Targets (2011) 0.75

A case report of simultaneous thrombosis of two coronary artery stents in association with clopidogrel resistance. Clin Cardiol (2007) 0.75

894: THE EFFECT OF INTRAVENOUS ACETAMINOPHEN ON OPIOID REQUIREMENTS AFTER CARDIAC SURGERY. Crit Care Med (2016) 0.75

Platelet-mediated thrombosis and drug-eluting stents. Circ Cardiovasc Interv (2011) 0.75

Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. Ann Pharmacother (2007) 0.75